| Ytd | -33.44% | |
| 1y | -26.83% |
| Open | 11.80 | Prev Close | 11.99 | Low | 11.80 | High | 12.13 | Mkt Cap | 3.01B |
| Vol | 1.33M | Avg Vol | 2.80M | EPS | 0.23 | P/E | 52.17 | Forward P/E | 18.37 |
| Beta | 1.18 | Short Ratio | 2.58 | Inst. Own | 51.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 14.11 | 200-d Avg | 14.84 | 1yr Est | 15.36 |
CLBT News
New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Cellebrite DI Ltd. (NASDAQ: CLBT - Get Free Report) has been given an average recommendation of "Mod
New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), ein weltweit führender Anbieter von KI-gestützten
/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), leader mondial des solutions numériques d'investi
New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Built around Cellebrite's industry-leading digital forensics capabilities, C-TEK helps forward-deplo
Bank of America Corp DE lessened its holdings in shares of Cellebrite DI Ltd. (NASDAQ: CLBT) by 11.5
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Boston, Massachusetts--(Newsfile Corp. - August 24, 2026) - Block & Leviton is investigating Cellebr
New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Cellebrite DI Ltd. (CLBT) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK,
Cellebrite DI Ltd. (CLBT) shares sold off after Q2 2026 annual recurring revenue of approximately $5
/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), ein weltweit führender Anbieter von KI-gestützten
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite DI Ltd. (CLBT) investors absorbed losses when shares sold off after the Company reported
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
Boston, Massachusetts--(Newsfile Corp. - August 17, 2026) - Block & Leviton is investigating Cellebr
Shareholders of Cellebrite DI Ltd. (CLBT) took losses when the stock sold off following Q2 2026 reve
NEW YORK--(BUSINESS WIRE)--Shareholders of Cellebrite DI Ltd. (CLBT) took losses when the stock sold
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers t
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers th
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price
Gainers BGIN Blockchain (NASDAQ:BGIN) stock rose 38.8% to $2.36 during Thursday's regular sessi
Shares of Cellebrite are trading sharply lower on Thursday following the release of second-quarter f
US stocks mixed, Nasdaq up more than 150 points. Dow down 0.16% to 53,682.87, Nasdaq up 0.61% to 26,
Cellebrite DI (NASDAQ:CLBT) reported second-quarter financial results on Thursday. The transcript fr
US stocks up, Dow gains over 100 points. Real estate sector rises, energy sector falls. Producer Pri
Gainers Yxt.Com Group Holding (NASDAQ:YXT) stock moved upwards by 47.5% to $6.68 during Thursday
Cellebrite DI (NASDAQ:CLBT) lowers FY2026 sales outlook from $565.000 million-$571.000 million to $5
Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $145.000 million-$148.000 million vs $150.298 million a
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.11 per share which met the analyst con
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises th
DA Davidson analyst Rudy Kessinger initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy r
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price
Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligen
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price
Cellebrite DI (NASDAQ:CLBT) sees FY2026 sales of $565.000 million-$571.000 million vs $554.864 milli
Cellebrite DI (NASDAQ:CLBT) sees Q1 sales of $126.000 million-$128.000 million vs $130.637 million a
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.14 per share which met the analyst con
Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mik
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises